hydroxychloroquine has been researched along with imatinib mesylate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baughman, R; Decker, C; Meyer, KC | 1 |
| Helgason, GV; Holyoake, TL; Karvela, M; Mukhopadhyay, A | 1 |
| Kalogirou, EM; Sklavounou, A; Tosios, KI | 1 |
| BrÜmmendorf, TH; Byrne, J; Clark, RE; Cong, W; Cony-Makhoul, P; Copland, M; Dixon-Hughes, J; Foroni, L; Gallipoli, P; Helgason, GV; Holyoake, TL; Horne, GA; Kelly, C; Koschmieder, S; Latif, AL; McMahon, L; Milojkovic, D; Mukhopadhyay, A; Nicolini, FE; Schafhausen, P; Smith, G; Stobo, J; Thomson, F | 1 |
| Eşkazan, AE | 1 |
| Bernal-Bello, D; Canalejo-Castrillero, E; Duarte-Millán, MÁ; Farfán-Sedano, AI; Frutos-Pérez, B; García de Viedma-García, V; Llarena-Barroso, C; Morales-Ortega, A; Ruiz-Giardín, JM; Ruiz-Ruiz, J; San Martín-López, JV | 1 |
| Capobianchi, MR; Castilletti, C; Ciccosanti, F; Colavita, F; Di Rienzo, M; Fimia, GM; Kepp, O; Kroemer, G; Piacentini, M; Sauvat, A; Zitvogel, L | 1 |
| Anglaret, X; Binquet, C; Bouchet, S; Crémer, A; Darnaud, T; Dupouy, J; Duvignaud, A; Gimbert, A; Joseph, JP; Journot, V; Lebeaux, D; Lebel, J; Lefèvre, B; Lhomme, E; Malvy, D; Michel, JF; Nguyen, D; Onaisi, R; Orne-Gliemann, J; Peiffer-Smadja, N; Piroth, L; Pistone, T; Poitrenaud, D; Richert, L; Roussillon, C; Sitta, R; Thiébaut, R; Wittkop, L | 1 |
| Rein, T | 1 |
3 review(s) available for hydroxychloroquine and imatinib mesylate
| Article | Year |
|---|---|
Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimetabolites; Autoimmune Diseases; Benzamides; Chloroquine; Cytotoxins; Drug Interactions; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Immunosuppression Therapy; Immunosuppressive Agents; Male; Piperazines; Pregnancy; Pyrimidines; Tumor Necrosis Factor-alpha | 2010 |
Drug-associated hyperpigmentation of the oral mucosa: report of four cases.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Biopsy; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Imatinib Mesylate; Male; Middle Aged; Minocycline; Mouth Mucosa; Protein Kinase Inhibitors | 2018 |
Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.
Topics: Antidepressive Agents; Antiviral Agents; Artesunate; Autophagy; Chloroquine; COVID-19 Drug Treatment; Drug Development; Drug Repositioning; Endoplasmic Reticulum; Endosomes; Humans; Hydroxychloroquine; Imatinib Mesylate; Infliximab; Intracellular Membranes; Ivermectin; Macrolides; Middle East Respiratory Syndrome Coronavirus; Niclosamide; Pandemics; RNA, Viral; SARS-CoV-2; Virus Replication | 2022 |
2 trial(s) available for hydroxychloroquine and imatinib mesylate
| Article | Year |
|---|---|
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Tolerance; Feasibility Studies; France; Hospitalization; Humans; Hydroxychloroquine; Imatinib Mesylate; Luxembourg; Outpatients; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Risk Reduction Behavior; SARS-CoV-2; Telmisartan; Therapies, Investigational; Treatment Outcome | 2020 |
4 other study(ies) available for hydroxychloroquine and imatinib mesylate
| Article | Year |
|---|---|
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2011 |
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
Topics: Cytogenetic Analysis; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2020 |
Imatinib for COVID-19: A case report.
Topics: Adult; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Hydroxychloroquine; Imatinib Mesylate; Lysosomes; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; RNA, Viral; SARS-CoV-2; Vero Cells; Viral Load; Virus Replication | 2020 |